<DOC>
	<DOCNO>NCT02177643</DOCNO>
	<brief_summary>Considering , Diacerein market almost 20 year , use continuously elderly patient osteoarthritis without present significant side effect , consider anti-hyperglycemic effect improvement insulin resistance observe animal model type 2 diabetes previously study Mexico . The aim study investigate effect Diacerein , medication anti-osteoarthritic property moderately analgesic activity , anti-inflammatory antipyretic , demonstrate inhibit property synthesis pro-inflammatory cytokine interleukin 1 ( IL-1 ) . Administered 12 week effect glycemic metabolic control patient diabetes mellitus 2 secondary failure metformin treatment .</brief_summary>
	<brief_title>Effect Diacerein Metabolic Control Patients With DM Type 2 Secondary Failure Metformin</brief_title>
	<detailed_description>This proof concept study aim access metabolic control patient type 2 diabetes mellitus secondary failure metformin . The Study Phase II , Multicenter , National , Prospective , Randomized , Double blind , Parallel Groups , Placebo Comparative Trial . UNICAMP ( Hospital Unicamp ) coordinate center participation State University Feira de Santana Center Diabetes Hypertension Fortaleza . Study Objectives : To investigate effect Diacerein administer 12 week ; glycemic metabolic control patient diabetes mellitus 2 secondary failure metformin treatment . The Total Number patient approximately 60 , 30 patient group .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Diabetes Complications</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Diacetylrhein</mesh_term>
	<criteria>Diabetes mellitus ( DM ) type 2 6 month 10 year disease Body mass index 25 35 kg/m2 Fasting glucose 120 250 mg/dL Glycated Hb A1c great 7,5 % Taking Metformin ( dose 1700 mg/day ) without secretagogue . Subjects DM1 Subjects DM2 use insulin Subjects DM2 chronic complication already clinical consequence Subjects type diabetes Creatinine serum great 1.4 mg/dl ( female ) 1.5 mg/dl ( male ) History heart disease and/or severe concomitant disease liver , coronary artery , renal History severe psychiatric neurological disorder History alcohol abuse and/or illegal drug psychotropic medicine past six month Hypersensitivity component study drug placebo formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diacerein</keyword>
</DOC>